Okay, Jon, good questions. In terms of next year, I touched on it briefly, but the $550 million, back from the Slide 17, I think it was, will be lower next year really partially because of reduced cash coming from DPL. But also, we're making reinvestments in a couple of businesses. As I mentioned, IPL and, secondly, Gener. The number of the-- so we expect that to be lower. We'll give you a better idea of what our expectations will be at our year-end call when we give you guidance. I think, though, the $500 million-ish range is a more indicative indication of a more normalized number. So this year would be closer to what we think would be a more normalized number. Next year, it'll be lower, below the -- below the, let's say, a $500 million normalized number really because of the reinvestments we're making. In terms of the CapEx, I said up to $200 million. I do mean up to $200 million. One of the biggest things -- it could be as little as half that amount. One of the issues is that Gener, it's been a great performer for us, great grower. They are building the 2 projects: coal and the hydro. Coal will come first, Cochrane I mentioned. But the issue was that they will need some equity at the Gener level to do that. And the $200 million would contemplate some equity being put in by AES. Obviously, another alternative is them issuing shares in the market to do that. So well-known company with good market cap, trades well, trades better than us. So as -- one of the things we'll think about is what the right funding is. To the extent that they access the majority of the equity they need in the markets, or maybe there's a splitting the baby concept, then that $200 million could be as little as $100 million to $125 million. That's just something we'll have to give some thought to. In terms of -- going back to the third part of your question, the 6 -- I think it's $6.2 billion of parent debt, including some trust preferreds, but we will look for coverage ratios. I think we've said that we want to maintain our rating and work it up over time. But the coverage ratio we look at in terms of debt-to-cash flow. I think we've used the range of 4.5 to 5.5. That continues to be a target that we've got. Near term, we're a little -- we're skewed towards the higher end of that range. That's why I said for '13, some of our cash flow available may be weighted more towards share repurchase. But once again, we see that as really a 2013-only focus. We've got the ability to do both, but we really focus -- kind of bottom line, we focus on the leverage, the coverage ratios. As you know, that's a more appropriate indication of credit quality.